Rapid Micro Biosystems (NASDAQ:RPID) and CardioGenics (OTCMKTS:CGNH) Head-To-Head Contrast

CardioGenics (OTCMKTS:CGNH) and Rapid Micro Biosystems (NASDAQ:RPID) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Valuation & Earnings

This table compares CardioGenics and Rapid Micro Biosystems”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
Rapid Micro Biosystems	$30.52 million	3.28	-$47.12 million	($1.07)	-2.06

CardioGenics has higher earnings, but lower revenue than Rapid Micro Biosystems.

Institutional & Insider Ownership

52.6% of Rapid Micro Biosystems shares are held by institutional investors. 41.4% of CardioGenics shares are held by insiders. Comparatively, 30.0% of Rapid Micro Biosystems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for CardioGenics and Rapid Micro Biosystems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
Rapid Micro Biosystems	1	0	1	0	2.00

Rapid Micro Biosystems has a consensus price target of $8.00, suggesting a potential upside of 263.64%. Given Rapid Micro Biosystems’ stronger consensus rating and higher possible upside, analysts clearly believe Rapid Micro Biosystems is more favorable than CardioGenics.

Profitability

This table compares CardioGenics and Rapid Micro Biosystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
Rapid Micro Biosystems	-140.30%	-95.40%	-58.85%

Risk & Volatility

CardioGenics has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, Rapid Micro Biosystems has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.